A citation-based method for searching scientific literature

J M Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, S Postel-Vinay, A Berdelou, A Varga, R Bahleda, A Hollebecque, C Massard, A Fuerea, V Ribrag, A Gazzah, J P Armand, N Amellal, E Angevin, N Noel, C Boutros, C Mateus, C Robert, J C Soria, A Marabelle, O Lambotte. Eur J Cancer 2016
Times Cited: 1179







List of co-cited articles
606 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex,[...]. J Clin Oncol 2018
20

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
19

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med 2018
18

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, Sunandana Chandra, Christian Menzer, Fei Ye, Shilin Zhao, Satya Das, Kathryn E Beckermann, Lisa Ha,[...]. JAMA Oncol 2018
895
16

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
12

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
12

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Filipe Martins, Latifyan Sofiya, Gerasimos P Sykiotis, Faiza Lamine, Michel Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex-Crosier,[...]. Nat Rev Clin Oncol 2019
603
12

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
Jeffrey S Weber, F Stephen Hodi, Jedd D Wolchok, Suzanne L Topalian, Dirk Schadendorf, James Larkin, Mario Sznol, Georgina V Long, Hewei Li, Ian M Waxman,[...]. J Clin Oncol 2017
653
12

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
11


Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
10

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
10

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
10

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan. Ann Oncol 2017
992
10

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
I Puzanov, A Diab, K Abdallah, C O Bingham, C Brogdon, R Dadu, L Hamad, S Kim, M E Lacouture, N R LeBoeuf,[...]. J Immunother Cancer 2017
940
10

Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok. Science 2018
10

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
9

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, John D Powderly,[...]. J Clin Oncol 2014
9

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang, Shouhao Zhou, Fang Yang, Xinyue Qi, Xin Wang, Xiaoxiang Guan, Chan Shen, Narjust Duma, Jesus Vera Aguilera, Ashish Chintakuntlawar,[...]. JAMA Oncol 2019
299
9

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
J C Osorio, A Ni, J E Chaft, R Pollina, M K Kasler, D Stephens, C Rodriguez, L Cambridge, H Rizvi, J D Wolchok,[...]. Ann Oncol 2017
349
9

Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals, Julie R Brahmer, Margaret K Callahan, Alejandra Flores-Chávez, Niamh Keegan, Munther A Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat, Maria E Suárez-Almazor. Nat Rev Dis Primers 2020
262
9

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.
Krista Dubin, Margaret K Callahan, Boyu Ren, Raya Khanin, Agnes Viale, Lilan Ling, Daniel No, Asia Gobourne, Eric Littmann, Curtis Huttenhower,[...]. Nat Commun 2016
511
8

Management of immune-related adverse events and kinetics of response with ipilimumab.
Jeffrey S Weber, Katharina C Kähler, Axel Hauschild. J Clin Oncol 2012
997
8


Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Jarushka Naidoo, Xuan Wang, Kaitlin M Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E Chaft, Neil H Segal, Margaret K Callahan, Alexander M Lesokhin,[...]. J Clin Oncol 2017
556
7

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
7

PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.
Raul S Gonzalez, Safia N Salaria, Caitlin D Bohannon, Aaron R Huber, Michael M Feely, Chanjuan Shi. Histopathology 2017
123
7

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, C Cauquil, P Chanson, M Collins, A Durrbach,[...]. Ann Oncol 2016
515
7

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Celine Boutros, Ahmad Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurelien Marabelle, Stephane Champiat, Armandine Berdelou,[...]. Nat Rev Clin Oncol 2016
565
7

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
7

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
François-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, Jean-Marie Michot, Emilie Routier, Laurent Taillade, Stéphane Champiat, Sandrine Aspeslagh, Julien Haroche, Laurence Albiges,[...]. Eur J Cancer 2018
164
7

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Troy Z Horvat, Nelly G Adel, Thu-Oanh Dang, Parisa Momtaz, Michael A Postow, Margaret K Callahan, Richard D Carvajal, Mark A Dickson, Sandra P D'Angelo, Kaitlin M Woo,[...]. J Clin Oncol 2015
652
7

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7


Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Mizuki Nishino, Anita Giobbie-Hurder, Hiroto Hatabu, Nikhil H Ramaiya, F Stephen Hodi. JAMA Oncol 2016
385
6

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
6

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
Claire F Friedman, Tracy A Proverbs-Singh, Michael A Postow. JAMA Oncol 2016
462
6

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
6

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
6

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
A M Menzies, D B Johnson, S Ramanujam, V G Atkinson, A N M Wong, J J Park, J L McQuade, A N Shoushtari, K K Tsai, Z Eroglu,[...]. Ann Oncol 2017
485
6

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
L Marthey, C Mateus, C Mussini, M Nachury, S Nancey, F Grange, C Zallot, L Peyrin-Biroulet, J F Rahier, M Bourdier de Beauregard,[...]. J Crohns Colitis 2016
180
6

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus, William H Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M Salay, Tracee L McMiller,[...]. J Clin Oncol 2010
6

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
Shintaro Iwama, Alessandra De Remigis, Margaret K Callahan, Susan F Slovin, Jedd D Wolchok, Patrizio Caturegli. Sci Transl Med 2014
369
6


Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Koichi Sato, Hiroaki Akamatsu, Eriko Murakami, Seigo Sasaki, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Yasuhiro Koh, Hiroki Ueda,[...]. Lung Cancer 2018
229
6

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Morganna Freeman-Keller, Youngchul Kim, Heather Cronin, Allison Richards, Geoffrey Gibney, Jeffrey S Weber. Clin Cancer Res 2016
512
6

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Mathieu Grangeon, Pascale Tomasini, Solene Chaleat, Arnaud Jeanson, Maxime Souquet-Bressand, Nataliya Khobta, Julien Bermudez, Youssef Trigui, Laurent Greillier, Marilyne Blanchon,[...]. Clin Lung Cancer 2019
84
7

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Frank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Charles Lance Cowey, Christopher D Lao, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. Lancet Oncol 2018
695
6

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Douglas B Johnson, Justin M Balko, Margaret L Compton, Spyridon Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, Igor Puzanov, Matthew R Alexander, Tyler L Bloomer,[...]. N Engl J Med 2016
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.